As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for the stock.

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

New account openings across four big lenders were down 5% in the second quarter from a year earlier. The lender forecast total income excluding notable items to exceed $21.61 billion as loan growth ...

Costco Wholesale Corporation (NASDAQ:COST) ranks among the best low volatility stocks to buy according to analysts.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

The S&P 500 closed at an all-time high for the ninth time this month, while the tech-heavy Nasdaq hit its 13th record July close. A jury rejected claims that the exchange operator broke its deal with ...